Takeaways

  • Recce Pharmaceuticals has cleared an Indonesian BPOM regulatory inspection of its Phase 3 DFI trial.
  • BPOM did not request any changes and reported no findings that would prevent the study from continuing.
  • Patient dosing is underway across five active clinical sites in the R327-G301 study.
  • The study is tracking toward an interim analysis.
  • Indonesian regulatory approval is anticipated in calendar 2026, with the country flagged as a near-term commercial opportunity.

As per 21 April ASX update, Recce Pharmaceuticals (ASX:RCE) has reached an important regulatory milestone, successfully clearing a routine inspection of one of its Indonesian Phase 3 clinical trial sites for diabetic foot infections (DFI). The inspection, carried out by Indonesia’s National Agency of Drug and Food Control (BPOM, also known as Badan POM), reviewed trial conduct, site processes, data integrity and compliance with Good Clinical Practice (GCP) standards.

Critically, the regulator did not request any changes to the ongoing trial and reported no findings that would prevent the study from continuing. The clean inspection outcome reduces Regulatory Risk around the registrational study and reinforces the integrity of Recce’s clinical operations in Indonesia.

The R327-G301 study and DFI opportunity

The R327-G301 Phase 3 study is Recce’s pivotal trial for its lead anti-infective candidate in diabetic foot infections — a high-burden condition affecting millions of patients globally. DFI is a serious complication of diabetes, with significant morbidity, hospitalisation costs and amputation risk. Existing antibiotic therapies face challenges including resistance, side-effect profiles and limited efficacy in chronic wounds.

Recce’s anti-infective platform is designed to address these limitations, with mechanism-of-action characteristics that may overcome resistance pathways limiting traditional antibiotics. The DFI indication provides a defined clinical and commercial entry point for the broader platform.

Why the inspection outcome matters

Regulatory inspections during ongoing Phase 3 trials assess multiple aspects of trial conduct, including study procedure adherence, informed consent processes, drug accountability, adverse event reporting and data integrity. An inspection without findings is a strong indicator that the trial is being conducted according to international standards.

For Recce, the clean BPOM inspection reduces the risk of regulatory delays at later approval stages. It also strengthens engagement with potential commercialisation partners, who typically prioritise regulatory compliance when evaluating potential licensing arrangements.

Patient dosing and trial progression

Patient dosing is underway in Recce’s registrational Phase 3 trial, with five clinical sites now active in Indonesia. The trial is tracking toward an interim analysis, providing one of the next major catalysts for the company’s Investment narrative.

Interim analyses provide statistical confirmation of trial trajectory and can de-risk later-stage development. For Phase 3 anti-infective programs, interim analyses also support discussions with regulators around Accelerated Approval pathways and potential public health considerations.

Indonesia as a near-term commercial opportunity

Recce has flagged Indonesia as a near-term commercial opportunity, with regulatory approval anticipated in calendar 2026. Indonesia represents a substantial market for diabetes-related complications, with growing diabetes prevalence, expanding healthcare access and a developing pharmaceutical infrastructure.

Approval in Indonesia would provide commercial Revenue, regulatory credibility for additional Jurisdiction filings and a foundation for broader Asian and global expansion. The Indonesian pathway also offers a relatively defined timeline compared with longer FDA or EMA approval processes for novel anti-infectives.

Why anti-infective programs matter strategically

Antimicrobial resistance (AMR) is one of the most significant global health challenges of the coming decade, with the World Health Organization, US Centers for Disease Control and other agencies warning of a potential post-antibiotic era. Novel anti-infective platforms with differentiated mechanisms are strategically important, supported by government programs including the US BARDA, the EU’s IMI and various national antimicrobial resistance initiatives.

Recce’s anti-infective platform sits within this strategic context, supported by an A$30 million Debt Facility for Phase 3 trial funding and an A$85 million R&Amp;D tax ruling that has improved its fiscal position.

Sector context: ASX anti-infective and infectious disease biotech

The ASX hosts a small cohort of anti-infective and infectious disease-focused biotechs, including Recce, Island Pharmaceuticals (ASX: ILA) and several other names. The segment has gained renewed attention as global AMR concerns have intensified and as government programs have expanded available development support.